![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, May 21, 2024 5:36:57 PM
BioElectronics Corporation Announces Utility Patent Application Filing
FREDERICK, MD - ( NewMediaWire ) - May 21, 2024 - BioElectronics Corporation ( https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today announces the filing of a new USPTO utility patent application addressing the treatment of chronic inflammation. This patent application, numbered 18/667,971, was a collaborative effort of John Martinez, Kenneth McLeod, PhD, and Richard Staelin, PhD. It outlines methods, systems, apparatuses, and devices that modify the immune response through non-invasive stimulation of the vagal nerves. The application draws from the results of a recently completed double-blind, placebo-controlled, canine study, published in Veterinary Medicine and Science which demonstrated that Pulsed Short Wave Therapy (PSWT) Technology applied to the vagal nerves of dogs diagnosed with osteoarthritis resulted in significant reductions in systemic discomfort.
Chronic inflammation poses a significant challenge to modern medicine. While few effective interventions exist, management of the condition often involves removing inflammatory triggers through dietary or lifestyle changes. Additionally, anti-inflammatory medications are commonly used, but their chronic use is costly and associated with significant side effects.
A promising approach for addressing chronic inflammation emerged with the discovery of the inflammatory reflex. Similar to reflexes in the somatic nervous system, this reflex involves both the afferent (incoming) and efferent (outgoing) arms of the vagus nerve. Although vagus nerve stimulation has been shown to suppress pro-inflammatory cytokine levels in the periphery, traditional stimulation techniques are not suitable for chronic vagus nerve stimulation.
BioElectronics’ PSWT technology and device designs overcome this limitation, providing a convenient, economical, and highly effective alternative for treating chronic inflammation. Given that over one-third of Americans suffer from chronic, systemic inflammation, this development opens an enormous new market opportunity for BioElectronics. The company plans to continue its efforts to provide clinical support and develop new designs for its product line.
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM